Table 2 Response to induction and... | American Society of Hematology

Table 2

Response to induction and consolidation therapy

	Good early responders	Poor early responders	All patients
No. patients	14	31	45
Early response, no.
CsS and ChS	14	0	14
CsR and ChS	0	6	6
CsS and ChR	0	17	17
CsR and ChR	0	8	8
After standard induction, no. (%)
Hematologic CR	14 (100)	NA	NA
PCR negativity*	4 (29)	NA	NA
Overall response to combined imatinib/chemotherapy, no. (%)†
Hematologic CR	14 (100)	29 (94)	43 (96)
Low PCR level*	10 (71)	18 (58)	28 (62)
PCR negativity*	9 (64)	8 (26)	17 (38)

	Good early responders	Poor early responders	All patients
No. patients	14	31	45
Early response, no.
CsS and ChS	14	0	14
CsR and ChS	0	6	6
CsS and ChR	0	17	17
CsR and ChR	0	8	8
After standard induction, no. (%)
Hematologic CR	14 (100)	NA	NA
PCR negativity*	4 (29)	NA	NA
Overall response to combined imatinib/chemotherapy, no. (%)†
Hematologic CR	14 (100)	29 (94)	43 (96)
Low PCR level*	10 (71)	18 (58)	28 (62)
PCR negativity*	9 (64)	8 (26)	17 (38)

CsS indicates corticosensitive; ChS, chemosensitive; CsR, corticoresistant; ChR, chemoresistant; NA, not applicable.

As defined in “Patients and methods.”

After HAMI consolidation in good early responders and after DIV combination in poor early responders.